BROOKS ENSIGN, MBA, M.Acc.
adi7b9@r.postjobfree.com
Education:
Harvard Business School – M.B.A.
National University – M.Acc.
Harvard College – B.A.
Experience:
Current role: Finance consultant for public NASDAQ company (recent IPO, >$250 Million)
2018-2020: Consulting roles: Interim Controller (publicly traded companies); SEC Reporting for ten companies (S-1, F-1, 10-K, 10-Q, XBRL); Revenue Recognition (ASC 606), Lease Accounting (ASC 842), IPO preparation, Purchase Accounting (ASC 805), Share-based Compensation (ASC 718); multiple ERP systems, W Desk, Active Disclosure, XBRL, Adaptive, Netsuite, Blackline, Carta. Director of Strategic Projects for Rose Ryan, Inc.: Led a team of technical accountants in Silicon Valley. IPO Advisory work with Connor Group, Protiviti and other accounting advisory firms. SaaS clients.
NERVANA SYSTEMS, INC. (acquired by Intel) 2016 – 2017
Controller
Full-time controller: first finance and accounting hire for venture-backed tech start-up; established accounting policies and procedures, managed accounts payable and accounts receivable, implemented accounting close and audit preparations, support for venture capital financing and M&A due diligence / integration. Business development for new Deep Learning artificial intelligence platform.
TEARLAB CORPORATION 2015
Interim Corporate Controller
Publicly traded (NASDAQ) medical device company; selected by CFO to lead accounting department in preparation for relocation to Texas. SEC Reporting: 10-K, Proxy and two 10-Qs. Year-end and quarter-end audit completion. Managed transition of audit firms, resulting in 30% savings. Accounting / finance leadership (led team of eight accountants). Monthly close and reconciliations review. Implemented three systems (Adaptive Planning, Equity Edge, and Concur).
ADVANCED BIOLOGICS 2013 – 2015
Controller
Profitable private medical device start-up company. Finance, accounting, corporate development, tax planning and human resources responsibilities. Selected new ERP system. Led ERP planning, design and implementation, including manufacturing modules implementation. Implemented new procedures, policies, and benefit programs. Corporate development support for corporate development transaction (sale of business).
BROOKS ENSIGN (cont’d)
HALOZYME THERAPEUTICS, INC. 2008 – 2009
Director of Financial Planning and Analysis
Strategic planning, portfolio valuation and review, corporate development analysis, and budgeting.
BAUSCH HEALTH (formerly VALEANT) 1995 – 2008
Director of SEC Reporting 2006 – 2008
Selected by CFO and Corporate Controller to be Director of SEC Reporting. Led corporate reporting team. Reviewed subsidiary controllers’ financial reporting for consolidated reporting. Responsible for SEC reporting, corporate financial reporting, accounting policy updates and interpretations, Sarbanes-Oxley compliance, investor relations support, quarterly close process, variance analysis, bond covenant compliance reporting, SFAS 123(R) reporting, external auditor relationship, XBRL preparations. Provided accounting guidance during strategic initiatives, including two strategic restructuring programs, the sale of European and Asian subsidiaries, and a worldwide collaboration with GlaxoSmithKline.
Director of Corporate Development / Finance FP&A)
1995 – 2006
Responsible for M&A financial planning and due diligence, financial planning for global marketing, future product commercialization and business development activities. Prominent Corporate Development team: M&A and licensing. Led due diligence and acquisition negotiations. Integral member of international corporate acquisitions team. Developed strategic five-year financial plans. Spearheaded congressional lobbying program.
Teaching Experience:
National University
2010-2021
Associate Faculty Instructor
Develop and teach courses in data analytics, accounting, finance and economics. SAS and Tableau.
Military Service:
UNITED STATES NAVY (combat veteran)
Commissioned as Ensign Ensign. Surface Warfare Officer: Navigator and Strike Warfare Officer.
Trained and led the team that launched the first Tomahawk missile launched in wartime.